Entero Healthcare Solutions Limited (NSE: ENTERO.NS) Stock Competitors & Peer Comparison

Entero Healthcare Solutions Limited (NSE: ENTERO.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ENTERO.NS stands at 62B. In comparison, EVERESTO.BO has a market cap of 2.9B. Regarding current trading prices, ENTERO.NS is priced at ₹1,423.60 on the NSE, while EVERESTO.BO trades at ₹297.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ENTERO.NS currently has a P/E ratio of 46.91, whereas EVERESTO.BO's P/E ratio is 52.25. In terms of profitability, ENTERO.NS's ROE is +0.07%, compared to EVERESTO.BO's ROE of +0.07%. Regarding short-term risk, ENTERO.NS is less volatile compared to EVERESTO.BO. This indicates lower risk in terms of short-term price fluctuations for ENTERO.NS.Check EVERESTO.BO's competition here

Entero Healthcare Solutions Limited (NSE: ENTERO.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ENTERO.NS stands at 62B. In comparison, QMSMEDI.NS has a market cap of 2.9B. Regarding current trading prices, ENTERO.NS is priced at ₹1,423.60 on the NSE, while QMSMEDI.NS trades at ₹148.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ENTERO.NS currently has a P/E ratio of 46.91, whereas QMSMEDI.NS's P/E ratio is 21.23. In terms of profitability, ENTERO.NS's ROE is +0.07%, compared to QMSMEDI.NS's ROE of N/A. Regarding short-term risk, ENTERO.NS is less volatile compared to QMSMEDI.NS. This indicates lower risk in terms of short-term price fluctuations for ENTERO.NS.Check QMSMEDI.NS's competition here

Entero Healthcare Solutions Limited (NSE: ENTERO.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ENTERO.NS stands at 62B. In comparison, ACHYUT.BO has a market cap of 1.7B. Regarding current trading prices, ENTERO.NS is priced at ₹1,423.60 on the NSE, while ACHYUT.BO trades at ₹7.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ENTERO.NS currently has a P/E ratio of 46.91, whereas ACHYUT.BO's P/E ratio is 700.00. In terms of profitability, ENTERO.NS's ROE is +0.07%, compared to ACHYUT.BO's ROE of +0.01%. Regarding short-term risk, ENTERO.NS is less volatile compared to ACHYUT.BO. This indicates lower risk in terms of short-term price fluctuations for ENTERO.NS.Check ACHYUT.BO's competition here

Entero Healthcare Solutions Limited (NSE: ENTERO.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ENTERO.NS stands at 62B. In comparison, RAMAVISION.BO has a market cap of 1.7B. Regarding current trading prices, ENTERO.NS is priced at ₹1,423.60 on the NSE, while RAMAVISION.BO trades at ₹161.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ENTERO.NS currently has a P/E ratio of 46.91, whereas RAMAVISION.BO's P/E ratio is 166.32. In terms of profitability, ENTERO.NS's ROE is +0.07%, compared to RAMAVISION.BO's ROE of +0.21%. Regarding short-term risk, ENTERO.NS is less volatile compared to RAMAVISION.BO. This indicates lower risk in terms of short-term price fluctuations for ENTERO.NS.Check RAMAVISION.BO's competition here

Entero Healthcare Solutions Limited (NSE: ENTERO.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ENTERO.NS stands at 62B. In comparison, BALAXI.NS has a market cap of 1.2B. Regarding current trading prices, ENTERO.NS is priced at ₹1,423.60 on the NSE, while BALAXI.NS trades at ₹22.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ENTERO.NS currently has a P/E ratio of 46.91, whereas BALAXI.NS's P/E ratio is -4.23. In terms of profitability, ENTERO.NS's ROE is +0.07%, compared to BALAXI.NS's ROE of +0.01%. Regarding short-term risk, ENTERO.NS is less volatile compared to BALAXI.NS. This indicates lower risk in terms of short-term price fluctuations for ENTERO.NS.Check BALAXI.NS's competition here

Entero Healthcare Solutions Limited (NSE: ENTERO.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ENTERO.NS stands at 62B. In comparison, BIJHANS.BO has a market cap of 642.2M. Regarding current trading prices, ENTERO.NS is priced at ₹1,423.60 on the NSE, while BIJHANS.BO trades at ₹85.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ENTERO.NS currently has a P/E ratio of 46.91, whereas BIJHANS.BO's P/E ratio is 570.80. In terms of profitability, ENTERO.NS's ROE is +0.07%, compared to BIJHANS.BO's ROE of N/A. Regarding short-term risk, ENTERO.NS is more volatile compared to BIJHANS.BO. This indicates higher risk in terms of short-term price fluctuations for ENTERO.NS.Check BIJHANS.BO's competition here

Entero Healthcare Solutions Limited (NSE: ENTERO.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ENTERO.NS stands at 62B. In comparison, VIVOBIOT.BO has a market cap of 428.5M. Regarding current trading prices, ENTERO.NS is priced at ₹1,423.60 on the NSE, while VIVOBIOT.BO trades at ₹19.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ENTERO.NS currently has a P/E ratio of 46.91, whereas VIVOBIOT.BO's P/E ratio is -23.55. In terms of profitability, ENTERO.NS's ROE is +0.07%, compared to VIVOBIOT.BO's ROE of -0.03%. Regarding short-term risk, ENTERO.NS is less volatile compared to VIVOBIOT.BO. This indicates lower risk in terms of short-term price fluctuations for ENTERO.NS.Check VIVOBIOT.BO's competition here

Entero Healthcare Solutions Limited (NSE: ENTERO.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ENTERO.NS stands at 62B. In comparison, RAJNISH.BO has a market cap of 396M. Regarding current trading prices, ENTERO.NS is priced at ₹1,423.60 on the NSE, while RAJNISH.BO trades at ₹0.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ENTERO.NS currently has a P/E ratio of 46.91, whereas RAJNISH.BO's P/E ratio is -6.50. In terms of profitability, ENTERO.NS's ROE is +0.07%, compared to RAJNISH.BO's ROE of -0.05%. Regarding short-term risk, ENTERO.NS is less volatile compared to RAJNISH.BO. This indicates lower risk in terms of short-term price fluctuations for ENTERO.NS.Check RAJNISH.BO's competition here

Entero Healthcare Solutions Limited (NSE: ENTERO.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ENTERO.NS stands at 62B. In comparison, CBPL.BO has a market cap of 376.5M. Regarding current trading prices, ENTERO.NS is priced at ₹1,423.60 on the NSE, while CBPL.BO trades at ₹49.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ENTERO.NS currently has a P/E ratio of 46.91, whereas CBPL.BO's P/E ratio is 12.35. In terms of profitability, ENTERO.NS's ROE is +0.07%, compared to CBPL.BO's ROE of +0.10%. Regarding short-term risk, ENTERO.NS is less volatile compared to CBPL.BO. This indicates lower risk in terms of short-term price fluctuations for ENTERO.NS.Check CBPL.BO's competition here

Entero Healthcare Solutions Limited (NSE: ENTERO.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ENTERO.NS stands at 62B. In comparison, MONOPHARMA.NS has a market cap of 149.3M. Regarding current trading prices, ENTERO.NS is priced at ₹1,423.60 on the NSE, while MONOPHARMA.NS trades at ₹8.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ENTERO.NS currently has a P/E ratio of 46.91, whereas MONOPHARMA.NS's P/E ratio is 4.83. In terms of profitability, ENTERO.NS's ROE is +0.07%, compared to MONOPHARMA.NS's ROE of N/A. Regarding short-term risk, ENTERO.NS is more volatile compared to MONOPHARMA.NS. This indicates higher risk in terms of short-term price fluctuations for ENTERO.NS.Check MONOPHARMA.NS's competition here

Entero Healthcare Solutions Limited (NSE: ENTERO.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ENTERO.NS stands at 62B. In comparison, NEXUSSURGL.BO has a market cap of 106.6M. Regarding current trading prices, ENTERO.NS is priced at ₹1,423.60 on the NSE, while NEXUSSURGL.BO trades at ₹19.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ENTERO.NS currently has a P/E ratio of 46.91, whereas NEXUSSURGL.BO's P/E ratio is 228.86. In terms of profitability, ENTERO.NS's ROE is +0.07%, compared to NEXUSSURGL.BO's ROE of +0.56%. Regarding short-term risk, ENTERO.NS is less volatile compared to NEXUSSURGL.BO. This indicates lower risk in terms of short-term price fluctuations for ENTERO.NS.Check NEXUSSURGL.BO's competition here

Entero Healthcare Solutions Limited (NSE: ENTERO.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ENTERO.NS stands at 62B. In comparison, NATURO.BO has a market cap of 51.5M. Regarding current trading prices, ENTERO.NS is priced at ₹1,423.60 on the NSE, while NATURO.BO trades at ₹2.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ENTERO.NS currently has a P/E ratio of 46.91, whereas NATURO.BO's P/E ratio is -5.93. In terms of profitability, ENTERO.NS's ROE is +0.07%, compared to NATURO.BO's ROE of -0.02%. Regarding short-term risk, ENTERO.NS is less volatile compared to NATURO.BO. This indicates lower risk in terms of short-term price fluctuations for ENTERO.NS.Check NATURO.BO's competition here

Entero Healthcare Solutions Limited (NSE: ENTERO.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ENTERO.NS stands at 62B. In comparison, EVOQ.BO has a market cap of 42.6M. Regarding current trading prices, ENTERO.NS is priced at ₹1,423.60 on the NSE, while EVOQ.BO trades at ₹1.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ENTERO.NS currently has a P/E ratio of 46.91, whereas EVOQ.BO's P/E ratio is -17.10. In terms of profitability, ENTERO.NS's ROE is +0.07%, compared to EVOQ.BO's ROE of -0.01%. Regarding short-term risk, ENTERO.NS is more volatile compared to EVOQ.BO. This indicates higher risk in terms of short-term price fluctuations for ENTERO.NS.Check EVOQ.BO's competition here